Madrigal Pharmaceuticals, Inc. MDGL
- Headquarters
- West Conshohocken, PA
- CEO
- William John Sibold
- Next results
- around Feb 18, 2027
MDGL among Health care peers
Six ratios from the latest 10-K. Each corner is the share of 154 peers the company is above, not a score.
What changed
42 new risk paragraphs. 10-K filed Feb 19, 2026 against Feb 26, 2025.
Each row opens the detail with the quote and the filing. A row is a change worth reading, not a verdict.
Accounting checks
11 checks on the latest 10-K. Checks, not verdicts.
0facts worth reading about all 11 checks found nothing to note
-
Receivables +149.9% ($53.8M to $134.5M) vs revenue +432.1% ($180.1M to $958.4M), -282.2 pts apart
-
Cash from operations −$189.6M vs net income −$288.3M (FY ending Dec 31, 2025)
-
Inventory +119.7% ($34.1M to $74.8M) vs revenue +432.1% ($180.1M to $958.4M), -312.4 pts apart
8 more checks with nothing to note
-
Same auditor in both 10-Ks: PricewaterhouseCoopers LLP
-
No statement of substantial doubt about going concern
-
No 8-K item 4.02 in the last 2 years
-
No NT 10-K or NT 10-Q in the last 2 years
-
The same matters as last year: Recognition of Product Revenue, Net
-
No sentence in the 10-K concludes that controls were not effective because of a material weakness
-
No 8-K item 2.06 in the last 2 years
-
No 8-K item 1.03 in the last 2 years
In their words
42 paragraphs in Risk Factors that were not in the 10-K filed Feb 26, 2025. Quoted as filed.
-
Item 1A · new paragraph · not in the 10-K filed Feb 26, 2025 10-K, ITEM 1A
A CMA is granted on the basis of less comprehensive clinical data than is normally required and is valid for one year, renewable annually, and subject to specific post-authorization obligations, such as clinical studies. If we fail to complete these obligations on time, if new data do not confirm a positive benefit-risk profile, or if…
-
Item 1A · new paragraph · not in the 10-K filed Feb 26, 2025 10-K, ITEM 1A
If we are unable to obtain or maintain adequate coverage and reimbursement from government or third-party payors for Rezdiffra or, if approved, any other product candidates, our prospects for generating revenue may be adversely affected.
-
Item 1A · new paragraph · not in the 10-K filed Feb 26, 2025 10-K, ITEM 1A
Government authorities and other third-party payors, such as private health insurers and health maintenance organizations, decide which medications they will pay for and establish reimbursement levels. The availability of coverage and extent of reimbursement by governmental and private payors is essential for most patients to be able to…
-
Item 1A · new paragraph · not in the 10-K filed Feb 26, 2025 10-K, ITEM 1A
Federal legislative and regulatory efforts to implement reference pricing or most-favored-nation pricing models could impact our product revenues and harm our business. On May 12, 2025, President Trump issued an executive order calling on pharmaceutical manufacturers to voluntarily reduce the prices of medicines in the U.S. and…
New risk paragraphs, against peers
Latest 10-K of each, Health care companies closest in revenue
Paragraphs in Risk Factors with nothing like them in the company's 10-K the year before. A count of text, not of risk.
Financial performance
Last 4 fiscal years · 10-K XBRL
| Metric | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
| Revenue | $0 | $0 | $180.1M | $958.4M |
| Net income | −$295.4M | −$373.6M | −$465.9M | −$288.3M |
| Operating cash flow | −$224.9M | −$324.2M | −$455.6M | −$189.6M |
| Free cash flow | −$225.1M | −$325.7M | −$457.0M | −$190.0M |
Revenue, FY2017 to FY2025
Ten fiscal years, each from its own 10-K · XBRL · USD
$958.4M ▲ 432.1% in FY2025−$288.3M in FY2025−$190.0M in FY2025
Recent filings
8 filings in the last 30 days · SEC EDGAR
-
BuyNov 6, 2026BAKER BROS. ADVISORS LP / Baker Bros. Advisors (GP) LLC / BAKER FELIX / BAKER JULIAN / 667, L.P. / Baker Brothers Life Sciences LP (Director) bought $35.0M open-market purchase on Nov 4, 2026
-
Planned saleNov 6, 2026SHANNON KELLEY (Officer) gave notice of a planned sale of 1,077 shares worth about $431K Form 144, approximate sale date Nov 6, 2026, under a 10b5-1 plan adopted Jul 31, 2026
-
Planned saleNov 3, 2026Carole Huntsman (Chief Commercial Officer) adopted a 10b5-1 trading plan reported in the 10-Q, up to 2,868 shares, runs to Jan 31, 2027
-
Planned saleNov 3, 2026Shannon Kelley (Chief Legal Officer) adopted a 10b5-1 trading plan reported in the 10-Q, up to 8,927 shares, runs to Sep 1, 2027
-
Planned saleNov 3, 2026Mardi Dier (Chief Financial Officer) adopted a 10b5-1 trading plan reported in the 10-Q, up to 8,875 shares, runs to Jul 31, 2027
About the company
Madrigal Pharmaceuticals, Inc., West Conshohocken, PA · from the 10-K filed Feb 19, 2026
We are a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (“MASH”), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, liver cancer, need for liver transplantation and premature mortality. MASH was previously known as nonalcoholic steatohepatitis (“NASH”). MASH is the leading cause of liver transplantation in women, the second leading cause of all liver transplantation in the United States and the fastest-growing indication for liver transplantation in Europe.
- Headquarters
- West Conshohocken, PA
- Country
- United States
- Reports in
- USD
- Listed on
- Nasdaq
- Fiscal year ends
- December 31
- Last results
- Nov 3, 2026
- Incorporated in
- DE
Email alerts
Sources
The 10-K filed Feb 19, 2026 (open at SEC), compared with the 10-K filed Feb 26, 2025. Numbers from the XBRL of the 10-Ks; filings from SEC EDGAR.
Work with it: Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/MDGL/export.csv") into a cell.